GERMANTOWN, Md., & VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx ...
Germantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal ...
QIAGEN N.V. QGEN announced the launch of QIAstat-Dx Gastrointestinal Panel 2 in the United States following the recent FDA clearance of the syndromic test for use in clinical settings. The launch ...
Gastrointestinal (GI) infections present a formidable challenge to healthcare systems. As we navigate this landscape, we recognize that there are numerous benefits when moving from conventional to ...
Background. Molecular syndromic diagnostic panels can enhance pathogen identification in the approximately 2–4 billion episodes of acute gastroenteritis that occur annually worldwide. However, the ...
New QIAstat-Dx Gastrointestinal Panel 2 Mini B&V (bacterial and viral) tailored to provide fast answers for outpatient diagnosis of gastrointestinal conditions QIAGEN the first to offer both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback